A Diagnosis and Treatment Optimization Study of Depression Based on the Neurological Mechanism of Reward System

Overview

Major depressive disorder (MDD) is a high-disabling disease. But its etiology and pathogenesis is not clear, and early recognition, diagnosis and treatment still has many challenges. Among numerous clinical manifestations of MDD, anhedonia is an important core symptom of MDD, especially in patients with melancholic features. Our previous studies and studies abroad have shown that MDD patients had functional abnormality in reward circuit. The abnormalities of reward-related core areas, such as the prefrontal cortex – nucleus accumbens – ventral tegmental area were closely associated with the development of MDD, and is an important neural basis of anhedonia. This study would take the reward circuit as mainline to carry out the etiology, diagnosis and therapeutic intervention studies of MDD. We would collect MDD patients with melancholic features and other populations with reward dysfunction. The neuroimaging techniques, stress assessment, genetic testing and drug intervention methods would be mainly used in this study. The functional connectivity of reward regions, such as the ventral striatum, nucleus accumben, and ventral medial prefrontal cortex, would be analyzed to identify the dysfunction of reward circuit of MDD, and its implication for early recognition, diagnosis and prediction of treatment efficacy of antidepressants. We would also investigate the effect of genetic and environmental factors on reward function of MDD and its biological basis. Finally, through modulating the reward circuit activity using animal experiments, we would verify and investigate reward dysfunction of MDD and its biological mechanisms. The project is expected to provide for new evidence for the establishment of reward mechanism – based objective diagnosis and treatment optimization strategy of MDD.

Full Title of Study: “Clinical Psychopharmacology Division,Institute of Mental Health,Peking University”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 30, 2021

Interventions

  • Drug: Escitalopram
    • receive escitalopram
  • Drug: Duloxetine
    • receive duloxetine
  • Drug: Mirtazapine
    • receive mirtazapine

Arms, Groups and Cohorts

  • Experimental: escitalopram
    • Eligible patients were assigned to escitalopram treatment based on investigators’ clinical practice.
  • Experimental: duloxetine
    • Eligible patients were assigned to duloxetine treatment based on investigators’ clinical practice.
  • Experimental: mirtazapine
    • Eligible patients were assigned to mirtazapine treatment based on investigators’ clinical practice.

Clinical Trial Outcome Measures

Primary Measures

  • Hamilton Rating Scale for Depression
    • Time Frame: 8 weeks
    • remission defined by Hamilton Rating Scale for Depression < 7

Participating in This Clinical Trial

Inclusion Criteria

  • first-episode, drug naive melancholic depression; remitted depression; schizophrenia patients; first-degree relatives of depressed patients. Exclusion Criteria:

  • major somatic diseases; DSM-IV axis I other mental illness; personality disorder, mental retardation; drug and / or alcohol dependence; serious suicidal tendencies or suicidal behavior; pregnant or lactating women; MRI contraindications.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Peking University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Si Tianmei, Director of Clinical Psychopharmacology Division Institute of Mental Health, Peking University – Peking University
  • Overall Contact(s)
    • Ji-Tao Li, MD, 010-62723742, ljt_102124@163.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.